Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arbutus Biopharma -- Ignore unavailable to you. Want to Upgrade?

To: donpat who wrote (10)	3/7/2014 11:31:59 AM
From: donpat	Respond to of 42

Tekmira’s three leading relationships in the RNAi therapeutics field are Alnylam Pharmaceuticals, Inc. of Cambridge, MA, Merck & Co. of Whitehouse Station, NJ, and F. Hoffman-La Roche Ltd. of Basel, Switzerland. Alnylam, Merck and Roche have all taken licenses to Tekmira’s lipid nanoparticle delivery technology and Tekmira is eligible to receive milestones and royalties on each and every product being developed that utilizes the company’s technology. investor.tekmirapharm.com